Report of the international symposium: Polycystic ovary syndrome: First Latin-American consensus

International Journal of Clinical Practice

Volumn 64, Issue 5, 2010, Pages 544-557

  Motta, A B ^a  

^a Centre de Estudios Farmacologicos y Botanicos   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANDROGEN; ANTIESTROGEN; CLOMIFENE CITRATE; GONADORELIN DERIVATIVE; GONADOTROPIN; INSULIN; LETROZOLE; METFORMIN; SIMVASTATIN;

ARGENTINA; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG DOSE INCREASE; FERTILIZATION IN VITRO; GESTATIONAL AGE; HUMAN; INFERTILITY; INSULIN RESISTANCE; LAPAROSCOPIC OVARIAN SURGERY; LAPAROSCOPIC SURGERY; LIFE; LIFESTYLE MODIFICATION; LIVER; LOW BIRTH WEIGHT; MULTIPLE PREGNANCY; NONHUMAN; OVARY; OVARY POLYCYSTIC DISEASE; PHENOTYPE; POPULATION; PRECOCIOUS PUBERTY; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SOUTH AMERICA; SOUTH AND CENTRAL AMERICA; SYNDROME X;

ADULT; ANDROGENS; ARGENTINA; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; FATTY LIVER; FEMALE; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INSULIN RESISTANCE; LIFE STYLE; METABOLIC SYNDROME X; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; PUBERTY, PRECOCIOUS; REPRODUCTIVE TECHNIQUES, ASSISTED;

EID: 77949399318     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02259.x     Document Type: Conference Paper

References (142)

1. Franks S. Polycystic ovary syndrome. N Engl J of Med 1995; 333: 853-61.
2. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434-38.
3. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome: a hypothesis. J Endocrinol 2002; 174: 1-5.
4. Carmina E. Mild androgen phenotypes. Best Pract Res Clin Endocrinol Metab 2006; 20: 207-20.
5. Carmina E, Azziz R. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. Fertil Steril 2006; 86: 7-8.
6. Azziz R, Carmina E, Dewailly D et al. Task Force on the Phenotype of the Polycystic Ovary Syndrome of the Androgen Excess and PCOS Society. Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91: 456-88.
7. Di Fede G, Mansueto P, Longo RA, Rini G, Carmina E. Influence of sociocultural factors on the ovulatory status of polycystic ovary syndrome. Fertil Steril 2009; 91: 1853-56.
8. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005; 90: 2545-49.
9. Ibañez L, Di Martino-Nardi J, Potau N, Saenger P. Premature adrenarche - normal variant or forerunner of adult disease? Endocr Rev 2000; 21: 671-96.
10. Ibañez L, Potau N, Francois I, de Zegher F. Precocious pubarche, hyperinsulinism and ovarian hyperandrogenism in girls: to reduced fetal growth. J Clin Endocrinol Metab 1998; 83: 3558-662.
11. Ibañez L, Potau N, Chacon P, Pascual C, Carrascosa A. Hyperinsulinemia, dyslipemia and cardiovascular risk in girls with a history of premature pubarche. Diabetologia 1998; 41: 1057-63.
12. Ibañez L, de Zegher F, Potau N. Anovulation after precocious pubarche: early markers and time course in adolescence. J Clin Endocrinol Metab 1999; 84: 2691-95.
13. Ibañez L, Castell C, Tresserras R, Potau N. Increased prevalence of type 2 diabetes mellitus and impaired glucose tolerance in firstdegree relatives of girls with a history of precocious pubarche. Clin Endocrinol 1999; 51: 395-401.
14. Ibañez L, Ong KO, Potau N, Marcos MV, de Zegher F, Dunger DB. Insulin gene VNTR genotype and the low birthweight, precocious pubarche and hyperinsulinism sequence. J Clin Endocrinol Metab 2001; 86: 5788-93.
15. Ibañez L, Valls C, Potau N, Marcos MV, de Zegher F. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birth-weight effect. Clin Endocrinol 2001; 55: 667-72.
16. Ibáñez L, Ferrer A, Ong K, Amin R, Dunger D, de Zegher F. Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr 2004; 144: 23-9.
17. Neville KA, Walker JL. Precocious pubarche is associated with SGA, prematurity, weight gain and obesity. Arch Dis Child 2005; 90: 258-61.
18. Meas T, Chevenne D, Thibaud E et al. Endocrine consequences of premature pubarche in post-pubertal Caucasian girls. Clin Endocrinol (Oxf) 2002; 57: 101-6.
19. Boonstra VH, Mulder PG, de Jong FH, Hokken-Koelega AC. Serum dehydroepiandrosterone sulfate levels and pubarche in short children born small for gestational age before and during growth hormone treatment. J Clin Endocrinol Metab 2004; 89: 712-17.
20. Ibañez L, Potau N, Zampolli M, Rique S, Saenger P, Carrascosa A. Hyperinsulinemia and decreased insulin-like growth factor binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche. J Clin Endocrinol Metab 1997; 82: 2283-8.
21. Mericq V. Low birth weight and endocrine dysfunction in postnatal life. Pediatr Endocrinol Rev 2006; 4: 3-14.
22. Rosenfield RL. Selection of children with precocious puberty for treatment with gonadotropin releasing hormone analogs. J Pediatr 1994; 124: 989-91.
23. Martí-Henneberg C, Vizmanos B. The duration of puberty in girls is related to the timing of its onset. J Pediatr 1997; 131: 618-21.
24. Ong KK, Dunger DB. Birth weight, infant growth and insulin resistance. Eur J Endocrinol 2004; 151: 131-9.
25. Eyzaguirre FC, Bancalari R, Youlton R et al. Precocious pubarche: experience in 173 cases. Rev Med Chil 2009; 137: 31-38.
26. Ibañez L, Ong KK, Mongan N et al. Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism. J Clin Endocrinol Metab 2003; 88: 3333-8.
27. Vottero A, Capelletti M, Giuliodori S et al. Decreased androgen receptor gene methylation in premature pubarche: a novel pathogenetic mechanism? J Clin Endocrinol Metab 2006; 91: 968-72.
28. Mesiano S, Katz SL, Lee JY, Jaffe RB. Insulin-like growth factors augment steroid production and expression of steroidogenic enzymes in human fetal adrenal cortical cells: implications for adrenal androgen regulation. J Clin Endocrinol Metab 1997; 82: 1390-6.
29. Silfen ME, Manibo A, Ferin M, Mc Mahon DJ, Levine LS, Oberfield SE. Elevated free IGF-I levels in prepubertal Hispanic girls with premature adrenarche: relationship with hyperandrogenism and insulin sensitivity. J Clin Endocrinol Metab 2002; 87: 398-403.
30. Guercio G, Rivarola MA, Chaler E, Maceiras M, Belgorosky A. Relationship between the GH ? IGF-I axis, insulin sensitivity, and adrenal androgens in normal prepubertal and pubertal boys. J Clin Endocrinol Metab 2002; 87: 1162-9.
31. Petry CJ, Ong KK, Michelmore KF et al. Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women. Hum Reprod 2005; 20: 1837-43.
32. Witchel SF, Ssmith R, Tomboc M, Aston CE. Candidate gene analysis in premature pubarche and adolescent hyperandrogenism. Fertil Steril 2006; 75: 724-30.
33. Barker DJ, Osmond C, Golding J, Kuh D, Wadsworth ME. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ 1989; 298: 564-7.
34. Barker DJP, Ball AR, Osmond C, Simons SJ. Fetal and placental size and risk of hypertension in adult life. BMJ 1990; 301: 259-62.
35. Barker DJP, Hales CN, Fall CHD, Osmond C, Phipps K, Clark PM. Type 2 (non-insulin dependent) diabetes mellitus, hypertension and hyperlipidemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993; 36: 62-7.
36. Hales CN, Barker DJP, Clark PM et al. Fetal and infant growth and impaired glucose tolerance at age 64. BMJ 1991; 303: 1019-22.
37. Bo S, Cavallo-Perin P, Scaglione L, Ciccone G, Pagano G. Low birth weight and metabolic abnormalities in twins with increased susceptibility to Type 2 diabetes mellitus. Diabet Med 2000; 17: 365-70.
38. Gluckman PD. The endocrine regulation of fetal growth in late gestation: the role of insulin-like growth factors. J Clin Endocrinol Metab 1995; 80: 1047-50.
39. Hay WW, Catz CS, Grave GD, Yaffe SJ. Workshop summary: fetal growth: its regulation and disorders. Pediatrics 1997; 99: 585-91.
40. Léger J, Oury JF, Noel M et al. Growth factors and intrauterine growth retardation. I. Serum growth hormone, insulin-like growth factor (IGF)-I, IGF-II, and IGF binding protein 3 levels in normally grown and growth-retarded human fetuses during the second half of gestation. Pediatr Res 1996; 40: 94-100.
41. Juul A, Bang P, Hertel NT et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994; 78: 744-52.
42. de Waal WJ, Hokken-Koelega AC, Stijnen T, de Muinck Keizer-Schrama SM, Drop SL. Endogenous and stimulated GH secretion, urinary GH excretion, and plasma IGF-I and IGF-II levels in prepubertal children with short stature after intrauterine growth retardation. The Dutch Working Group on Growth Hormone. Clin Endocrinol (Oxf) 1994; 41: 621-30.
43. Boguszewski M, Jansson C, Rosberg S, Albertsson-Wikland A. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age. J Clin Endocrinol Metab 1996; 81: 3902-8.
44. Johnston LB, Dahlgren J, Leger J et al. Association between insulin-like growth factor I (IGF-I) polymorphisms, circulating IGF-I, and pre- and postnatal growth in two European small for gestational age populations. J Clin Endocrinol Metab 2003; 88: 4805-10.
45. Verkauskiene R, Jaquet D, Deghmoun S, Chevenne D, Czernichow P, Levy-Marchal C. Smallness for gestational age is associated with persistent change in insulin-like growth factor I (IGF-I) and the ratio of IGF-I ? IGF-binding protein-3 in adulthood. J Clin Endocrinol Metab 2005; 90: 5672-6.
46. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome: relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 1995; 96: 520-7.
47. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992; 41: 1257-66.
48. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 29: 617-23.
49. Sutton ML, Gilchrist RB, Thompson JG. Effects of in-vivo and in- vitro environments on the metabolism of the cumulus-oocyte complex and its influence on oocyte developmental capacity. Hum Reprod Update 2003; 9: 35-48.
50. Okon MA, Laird SM, Tuckerman EM, Li TC. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fert Steril 1998; 69: 682-90.
51. Tuckerman EM, Okon MA, Li T, Laird SM. Do androgens have a direct effect on endometrial function? An in vitro study. Fertil Steril 2000; 74: 771-9.
52. Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Perez-Bravo F, Recabarren SE. Maternal serum androgens in pregnant women with polycystic ovary syndrome: possible implications in prenatal androgenization. Hum Reprod 2002; 17: 2573-9.
53. Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update 2001; 7: 522-5.
54. Pillay OC, Te Fong LF, Crow JC et al. The association between polycystic ovaries and endometrial cancer. Hum Reprod 2006; 21: 924-9.
55. Jakubowicz DJ, Essah PA, Seppala M et al. Reduced serum glycodelin and insulin-like growth factor-binding protein-1 in women with polycystic ovary syndrome during first trimester of pregnancy. J Clin Endocrinol Metab 2004; 89: 833-9.
56. Luchetti CG, Mikó E, Szekeres-Bartho J, Paz DA, Motta AB. Dehydroepiandrosterone and metformin modulate progesteroneinduced blocking factor (PIBF), cyclooxygenase 2 (COX2) and cytokines in early pregnant mice. J Steroid Biochem Mol Biol 2008; 111: 200-7.
57. Ajossa S, Guerriero S, Paoletti AM, Orrù M, Melis GB. The antiandrogenic effect of flutamide improves uterine perfusion in women with polycystic ovary syndrome. Fertil Steril 2002; 77: 1136-40.
58. Palomba S, Russo T, Orio F Jr et al. Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. Hum Reprod 2006; 21: 457-65.
59. Strowitzki T, von Eye HC, Kellerer M, Häring HU. Tyrosine kinase activity of insulin-like growth factor I and insulin receptors in human endometrium during the menstrual cycle: cyclic variation of insulin receptor expression. Fertil Steril 1993; 59: 315-22.
60. Matsumoto H, Sakai K, Iwashita M. Insulin-like growth factor binding protein-1 induces decidualization of human endometrial stromal cells via alpha 5 beta 1 integrin. Mol Hum Reprod 2008; 14: 485-9.
61. Giudice LC. Endometrium in PCOS: implantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab 2006; 20: 235-44.
62. Chi MY, Schlein AL, Moley KH. High insulin-like growth factor 1 (IGF-1) and insulin concentrations trigger apoptosis in the mouse blastocyst via down-regulation of the IGF-1 receptor. Endocrinology 2000; 141: 4784-92.
63. Doster JA, Purdum MB, Martin LA, Goven AJ, Moorefield R. Gender differences, anger expression, and cardiovascular risk. J Nerv Ment Dis 2009; 197: 552-4.
64. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
65. Rizzo M, Rini GB, Carmina E. Androgen excess and cardiovascular risk. Minerva Endocrinol 2007; 32: 67-71.
66. Talbott EO, Guzick DS, Sutton-Tyrrell K et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000; 20: 2414-21.
67. Christian RC, Dumesic DA, Behrenbeck T, Oberg A, Sheedy PF, Fitzpatrick L. Prevalence and predictors of coronary artery calcifi-cation in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 2562-8.
68. Guzick DS. Cardiovascular risk in PCOS. J Clin Endocrinol Metab 2004; 89: 3694-5.
69. Orio F, Palomba S, Spinelli L et al. The cardiovascular risk of young women with polycystic. J Clin Endocrinol Metab 2004; 89: 3696-701.
70. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1357-63.
71. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495-506.
72. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM 2006; 99: 1-14.
73. Genctoy G, Ozbek M, Avcu N et al. Gingival health status in renal transplant recipients: relationship between systemic inflammation and atherosclerosis. Int J Clin Pract 2007; 61: 577-82.
74. Rizzo M, Berneis K, Hersberger M et al. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod 2009; 24: 2286-92.
75. Reeder SB, Robson PM, Yu H et al. Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling. J Magn Reson Imaging 2009; 26: 1332-9.
76. Rafiq N, Younossi ZM. Nonalcoholic fatty liver disease: a practical approach to evaluation and management. Clin Liver Dis 2009; 13: 249-66.
77. Fukushima J, Kamada Y, Matsumoto H et al. Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization. Hepatol Res 2009; 39: 724-38.
78. Lemoine M, Ratziu V, Kim M et al. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int 2009; 29: 1291-3.
79. Milner KL, van der Poorten D, Xu A et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 2009; 9: 1926-34.
80. Kim HC, Kim DJ, Huh KB. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis 2009; 204: 521-5.
81. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 2007; 5: 496-501.
82. Cerda C, Pérez-Ayuso RM, Riquelme A et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 2007; 47: 313-5.
83. Markou A, Androulakis II, Mourmouris C et al. Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. Fertil Steril 2009; (in press).
84. Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ. Non-alcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 741-7.
85. Maclaren NK, Gujral S, Ten S, Motagheti R. Childhood obesity and insulin resistance. Cell Biochem Biophys 2007; 48: 73-8.
86. Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A. Obesity and reproductive disorders in women. Hum Reprod Update 2003; 9: 359-72.
87. Froen JF, Arnestad M, Frey K, Vege A, Saugstad OD, Stray-Pedersen B. Risk factors for sudden intrauterine unexplaineddeath: epidemiologic characteristics of singleton cases in Oslo, Norway, 1986-1995. Am J Obstet Gynecol 2001; 184: 694-702.
88. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006; 12: 673-83.
89. Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab 1999; 84: 1617-22.
90. Imani B, Eijkemans MJ, de Jong FH et al. Free androgen index and leptin are the most prominent endocrine predictors of ovarian response during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab 2000; 85: 676-82.
91. Imani B, Eijkemans MJ, de Velde ER, Habbema JD, Fauser BC. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril 2002; 77: 91-7.
92. Mulders AG, Laven JS, Eijkemans MJ, Hughes EG, Fauser BC. Patient predictors for outcome of gonadotrophin ovulation induction in women with normogonadotrophic anovulatory infertility: a meta-analysis. Hum Reprod Update 2003; 9: 429-49.
93. Balen AH, Platteau P, Andersen AN et al. The influence of body weight on response to ovulation induction with gonadotrophins in 335 women with World Health Organization group II anovulatory infertility. BJOG 2006; 113: 1195-202.
94. Gjonnaess H. Ovarian electrocautery in the treatment of women with polycystic ovary syndrome (PCOS). Factors affecting the results. Acta Obstet Gynecol Scand 1994; 73: 407-12.
95. Moran LJ, Brinkworth G, Noakes M, Norman RJ. Effects of lifestyle modification in polycystic ovarian syndrome. Reprod Biomed Online 2006; 12: 569-78.
96. Kiddy DS, Hamilton-Fairley D, Bush A et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 36: 105-11.
97. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346: 591-602.
98. Sjostrom L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-93.
99. Wadden TA, Berkowitz RI, Womble LG et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 2111-20.
100. Homburg R. Clomiphene citrate-end of an era? A mini-review. Hum Reprod 2005; 20: 2043-51.
101. Legro RS, Barnhart HX, Schlaff WD et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356: 551-66.
102. Hammond MG, Halme JK, Talbert LM. Factors affecting the pregnancy rate in clomiphene citrate induction of ovulation. Obstet Gynecol 1983; 62: 196-202.
103. Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update 1997; 3: 359-65.
104. Eijkemans MJ, Imani B, Mulders AG, Habbema JD, Fauser BC. High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). Hum Reprod 2003; 18: 2357-62.
105. Palomino WA, Fuentes A, González RR et al. Differential expression of endometrial integrins and progesterone receptor during the window of implantation in normo-ovulatory women treated with clomiphene citrate. Fertil Steril 2005; 83: 587-93.
106. Nestler JE, Stovall D, Akhter N, Iuorno MJ, Jakubowicz DJ. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 2002; 78: 653-4.
107. Cheang KI, Nestler JE. Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome? Reprod Biomed Online 2004; 8: 440-7.
108. Cheang KI, Sharma ST, Nestler JE. Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? Gynecol Endocrinol 2006; 22: 595-604.
109. Carrington B, Sacks G, Regan L. Recurrent miscarriage: pathophysiology and outcome. Curr Opin Obstet Gynecol 2005; 17: 591-7.
110. Davies MJ. Fetal programming: the perspective of single and twin pregnancies. Reprod Fertil Dev 2005; 17: 379-386.
111. Patel SM, Nestler JE. Fertility in polycystic ovary syndrome. Endocrinol Metab Clin North Am 2006; 35: 137-55.
112. Bruni V, Dei M, Pontello V, Vangelisti P. The management of polycystic ovary syndrome. Ann N Y Acad Sci 2003; 997: 307-21.
113. Glueck CJ, Goldenberg N, Streicher P, Wang P. The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin. Expert Opin Pharmacother 2002; 3: 1557-68.
114. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17: 2858-64.
115. Glueck CJ, Streicher P, Wang P. Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin Pharmacother 2002; 3: 1177-89.
116. Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002; 77: 520-5.
117. Simmons D, Walters BN, Rowan JA, McIntyre HD. Metformin therapy and diabetes in pregnancy. Med J Aust 2004; 180: 462-4.
118. Ben-Haroush A, Yogev Y, Fisch B. Insulin resistance and metformin in polycystic ovary syndrome. Eur J Obst Gynecol Reprod Biol 2004; 115: 125-33.
119. Creanga AA, Bradley HM, McCormick C, Witkop CT. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gynecol 2008; 111: 959-68.
120. Motta DA. Metformin in the treatment of polycystic ovary syndrome. Curr Pharm Des 2008; 14: 2121-5.
121. McGovern PG, Carson SA, Barnhart HX et al. Medication adherence and treatment success in the National Institute of Child Health and Human Development-Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome Trial. Fertil Steril 2008; 90: 1283-6.
122. Brown JB. Pituitary control of ovarian function-concepts derived from gonadotrophin therapy. Aust N Z J Obstet Gynaecol 1978; 18: 46-54.
123. Baird DT. A model for follicular selection and ovulation: lessons from superovulation. J Steroid Biochem 1987; 27: 15-23.
124. Dale O, Tanbo T, Lunde O, Abyholm T. Ovulation induction with low-dose follicle-stimulating hormone in women with the polycystic ovary syndrome. Acta Obstet Gynecol Scand 1993; 72: 43-6.
125. Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 1997; 18: 71-106.
126. Balasch J, Fabregues F, Creus M, Puerto B, Penarrubia J, Vanrell JA. Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens. Hum Reprod 2001; 16: 652-6.
127. Christin-Maitre S, Hugues JN. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum Reprod 2003; 18: 1626-31.
128. van Santbrink EJ, Donderwinkel PF, van Dessel TJ, Fauser BC. Gonadotrophin induction of ovulation using a step-down dose regimen: single-centre clinical experience in 82 patients. Hum Reprod 1995; 10: 1048-53.
129. Hugues JN, Cedrin-Durnerin I, Howles CM et al. The use of a decremental dose regimen in patients treated with a chronic low-dose step-up protocol for WHO Group II anovulation: a prospective randomized multicentre study. Hum Reprod 2006; 21: 2817-22.
130. Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab 2007; 92: 456-61.
131. Rizzo M, Berneis K, Carmina E, Rini GB. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome? Am J Obstet Gynecol 2008; 198: 1-5.
132. Eckmann KB, Kockler DR. Aromatase inhibitors for ovulation and pregnancy in polycystic ovary syndrome. Ann Pharmacother 2009; 43: 1338-46.
133. Ganesh A, Goswami SK, Chattopadhyay R, Chaudhury K, Chakravarty B. Comparison of letrozole with continuous gonadotropins and clomiphene- gonadotropin combination for ovulation induction in 1387 PCOS women after clomiphene citrate failure: a randomized prospective clinical trial. J Assist Reprod Genet 2009; 26: 19-24.
134. Badawy A, Mosbah A, Tharwat A, Eid M. Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol. Fertil Steril 2009; 92: 236-9.
135. Casper RF. Aromatase inhibitors in ovarian stimulation. J Steroid Biochem Mol Biol 2007; 106: 71-5.
136. Gjönnaess H. Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. Fertil Steril 1984; 41: 20-5.
137. Bayram N, van Wely M, Kaaijk EM, Bossuyt PM, Veen vander F. Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. BMJ 2004; 328: 192-6.
138. Kaya H, Sezik M, Ozkaya O. Evaluation of a new surgical approach for the treatment of clomiphene citrate-resistant infertility in polycystic ovary syndrome: laparoscopic ovarian multi-needle intervention. J Minim Invasive Gynecol 2005; 12: 355-8.
139. van Santbrink EJ, Fauser BC. Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low dose step-up and step-down dose regimens. J Clin Endocrinol Metab 1997; 82: 3597-602.
140. Eijkemans MJ, Polinder S, Mulders AG, Laven JS, Habbema JD, Fauser BC. Individualized cost-effective conventional ovulation induction treatment in normogonadotrophic anovulatory infertility (WHO group 2). Hum Reprod 2005; 20: 2830-7.
141. Heijnen EM, Eijkemans MJ, De Klerk C et al. A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial. Lancet 2007; 369: 743-9.
142. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Hum Reprod 2008; 23: 462-77.